Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.



		Treatment Name:		2009-0759: A Phase 2 Open-Label Study of TPI 287 in Patients with Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy with Radiation plus Temozolomide

		Keywords:		TPI 287

		Phase:		Phase 2

		Treatment ID#s:		VT2024

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: N Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Recurrent or progressive glioblastoma

		Last Updated:		05/11/2011

		Tumor Types:		Glioblastoma Multiforme


		Comments:		TPI 287 is a new anti-microbubule agent manufactured from naturally occurring taxanes, but modified to overcome resistance to taxanes and bind to mutant tubulin. In laboratory experiments it was greatly more active against multidrug-resistant cell lines than other compounds tested, and more active in animal model tumors of multidrug-resistant cell lines. Phase I testing showed little or no toxicity from TPI 287, which is able to cross the blood-brain barrier and achieve pharmacologically relevant levels.

		Treatment Type:		Chemotherapy.

		Contact:		MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/